Datopotamab deruxtecan, 1 mg
Products billed under this code include Datroway.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Datroway.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Datroway | Daiichi Sankyo Inc. | 65597-0801-01 | 100 | $5,250.50 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $52.505 | +$0.006 | 1 MG | Datopotamab deruxtecan, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $52.499 | +$0.983 | 1 MG | Datopotamab deruxtecan, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $51.516 | −$0.036 | 1 MG | Datopotamab deruxtecan, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $51.552 | −$0.006 | 1 MG | Datopotamab deruxtecan, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $51.558 | – | 1 MG | Datopotamab deruxtecan, 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.